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eply
r. Handelsman raises concerns with regard to the interpretation
f findings in the recently published study by Caminiti et al. (1)
nd our accompanying editorial (2). His major point is related to
estosterone’s failure to improve cardiac function while having
eneficial peripheral effects—a dichotomy he suggests may be
xplained by the mood-elevating effects of testosterone. He also
aises concerns with regard to the suboptimal use of saline as
lacebo.
We have no problems with agreeing with Dr. Handelsman’s
iew, and these aspects should be taken into account in the
nterpretation of the effects of testosterone in heart failure. In fact,
he interaction between hormones such as testosterone, neuro-
ransmitters, and inflammatory markers such as cytokines is an
ttractive target for therapy in several disorders such as chronic
eart failure. Thus, if this mechanism contributes to the results of
he study by Caminiti et al. (1), it should encourage rather than
dvise against further studies in this field. Moreover, although the
uthors did not find any effect on myocardial function, further
ong-term studies are needed before making any firm conclusions.
here is clearly a need for new treatment modalities in heart
ailure, and testosterone supplementation might be an interesting
pproach, most probably operating through several mechanisms
ncluding those suggested by Dr. Handelsman.
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2009;54:928–9. pilated Cardiomyopathy
omplicates Pregnancy Outcome:
ut How?
n a recent issue of the Journal, Grewal et al. (1) showed that the
isk of adverse maternal events in pregnant women with dilated
ardiomyopathy (DCM) is considerable, but the underlying mech-
nisms (in addition to increased hemodynamic load) remain
ncertain. Medication was discontinued in many of the women
efore pregnancy or during the first trimester. Even without the
hysical burden of pregnancy, withdrawal of heart failure medica-
ion per se may lead to dramatic hemodynamic deterioration. It
hus would be interesting to know whether the pregnant women
hose medication was discontinued fared worse than those who
ontinued to take their normal medication. It should be noted that
everal beta-blockers, notably labetalol, can be used safely during
regnancy. Thus, pregnancy outcome may not be quite as dismal as
eported by Grewal et al. (1) when adequate therapy is provided.
Four of the 9 cases of heart failure occurred after delivery (1).
xidative stress rises during normal pregnancy, culminating in the
ast trimester. Several signaling pathways have been shown to be
ecessary for protecting the maternal heart, including STAT3. In
mouse model, a deletion of STAT3 caused proteolytic cleavage of
rolactin into a potent antiangiogenic, proapoptotic, and proin-
ammatory factor associated with the development of peripartum
ardiomyopathy (2). It is conceivable that peripartum oxidative
tress caused additional damage to the left ventricle. In this respect,
he fact that 5 women had doxorubicin-induced DCM may be
elevant, because oxidative stress is deemed to play an important
ole in this type of DCM. It thus would be interesting to know
hether Grewal et al. (1) found a difference in pregnancy outcome
etween the women with doxorubicin-induced DCM versus idio-
athic DCM.
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eply
e thank Dr. van den Berg and colleagues for their interest in our
aper (1), and agree that in addition to the increased hemodynamic
l
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May 18, 2010:2290–2oad imposed by pregnancy, discontinuation of cardiac medications
an contribute to cardiac decompensation in pregnant women with
dilated cardiomyopathy. We acknowledged this as a limitation in
ur ability to determine accurately the direct role of pregnancy on
utcomes in this population.
Angiotensin-converting enzyme inhibitors are associated with
n increased fetal risk of major congenital malformations, and
herefore are not used in pregnancy (2,3). Because there is a
otential for reduction in intravascular volume with diuretics and
n effect on uteroplacental perfusion, we typically use only diuretics
o treat congestive symptoms (4,5). We agree, however, that
reatment with beta-blockers throughout pregnancy would be
ptimal, and our current practice is to encourage continued use of
eta-blockers. However, beta-blocker therapy for heart failure was
ot used as routinely in the early 1990s at the beginning of our
ohort recruitment. Furthermore, some women referred to our
enter already had stopped medications on the advice of the
eferring physician and others elected to stop when the fetal risk of
eta-blockers was discussed (6,7). Thus, there were many reasons
hat the use of beta-blocker therapy was low in this study.
We were unable to compare outcomes adequately among
omen who continued versus discontinued medications primarily
ecause of the small sample size. First, all women stopped taking
ngiotensin-converting enzyme inhibitors after the initial assess-
ent. There were only 7 women undergoing diuretic therapy at
he first antenatal visit, and diuretics were continued in only 5
omen. Beta-blocker therapy was continued in all women (n 
3) who were taking it at our first assessment. The adverse cardiac
vent rate during pregnancy for women taking beta-blockers was
8% (5 of 13) compared with 39% (9 of 23) in women not taking
beta-blocker.
Finally, in our series there were 5 women with doxorubicin-
nduced dilated cardiomyopathy. We did not observe an increase in
he event rates among women with doxorubicin-induced cardio-
yopathy compared with those with idiopathic dilated cardiomy-pathy. It is possible that oxidative stress during pregnancy may
lay a role in cardiac decompensation. However, a larger sample of
omen would be needed to answer this question.
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